Embla Medical Reports Strong Q4 2024 Performance

Ossur hf ( (OSSFF) ) has released its Q4 earnings. Here is a breakdown of the information Ossur hf presented to its investors.

Embla Medical hf, a company in the healthcare sector, specializes in prosthetic and orthotic solutions. In its latest earnings report for Q4 2024, the company reported sales of USD 225 million, with a 5% organic growth rate. The Prosthetics & Neuro Orthotics division was a standout, showing a 12% increase in sales. The company achieved a robust EBITDA margin of 21% for the quarter, reflecting strong operational performance and cost control measures. Over the full year, Embla Medical’s organic sales growth was 6%, supported by the acquisition of Fior & Gentz and ongoing product innovation. The company anticipates continued growth in 2025, projecting an organic sales increase of 5-8% and maintaining an EBITDA margin of 20-21%. These figures underscore the company’s strategic focus on expanding its market presence and enhancing operational efficiency.